Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Analysts give Sagimet a consensus rating of Moderate Buy (8 buy, 2 hold, 1 sell) with an average 12‑month price target of $26.25, versus a current share price around $5.24 and a market cap near $170.7M.
• Sagimet is a clinical‑stage biotech whose lead program, CM‑101, is a first‑in‑class fusion protein targeting CCL24 to treat fibrotic diseases and is in early clinical evaluation for indications such as NASH and systemic sclerosis.
• Insider activity: CEO David Happel sold 12,101 shares at $5.36 (reducing his stake by ~1.75%); insiders own about 14.7% of the stock while institutional ownership is roughly 87.9%.

Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eleven brokerages that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $26.25.

Several equities analysts recently issued reports on SGMT shares. Wall Street Zen upgraded Sagimet Biosciences from a "sell" rating to a "hold" rating in a research note on Saturday, March 14th. Barclays assumed coverage on shares of Sagimet Biosciences in a research note on Tuesday, January 27th. They set an "equal weight" rating and a $8.00 price objective for the company. Guggenheim started coverage on Sagimet Biosciences in a research report on Tuesday, February 3rd. They issued a "buy" rating and a $27.00 target price for the company. HC Wainwright restated a "buy" rating and issued a $29.00 price target on shares of Sagimet Biosciences in a report on Wednesday, March 11th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Sagimet Biosciences in a research report on Thursday, January 22nd.

Insider Buying and Selling at Sagimet Biosciences

In related news, CEO David Happel sold 12,101 shares of the company's stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an average price of $5.36, for a total transaction of $64,861.36. Following the sale, the chief executive officer directly owned 677,621 shares of the company's stock, valued at approximately $3,632,048.56. This represents a 1.75% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 14.70% of the company's stock.

Institutional Trading of Sagimet Biosciences

Institutional investors and hedge funds have recently made changes to their positions in the stock. AlphaQuest LLC bought a new position in shares of Sagimet Biosciences during the third quarter worth about $804,000. American Century Companies Inc. boosted its holdings in shares of Sagimet Biosciences by 8.9% in the second quarter. American Century Companies Inc. now owns 42,285 shares of the company's stock valued at $322,000 after acquiring an additional 3,454 shares in the last quarter. OMERS ADMINISTRATION Corp bought a new position in shares of Sagimet Biosciences in the fourth quarter valued at approximately $316,000. BNP Paribas Financial Markets increased its stake in shares of Sagimet Biosciences by 9,168.2% during the second quarter. BNP Paribas Financial Markets now owns 26,785 shares of the company's stock valued at $204,000 after acquiring an additional 26,496 shares during the period. Finally, XTX Topco Ltd raised its holdings in Sagimet Biosciences by 137.0% during the second quarter. XTX Topco Ltd now owns 25,624 shares of the company's stock worth $195,000 after purchasing an additional 14,813 shares in the last quarter. 87.86% of the stock is currently owned by institutional investors and hedge funds.

Sagimet Biosciences Price Performance

SGMT opened at $5.24 on Thursday. The stock's 50 day simple moving average is $5.44 and its 200 day simple moving average is $6.41. The stock has a market cap of $170.72 million, a P/E ratio of -3.34 and a beta of 3.17. Sagimet Biosciences has a 1-year low of $1.73 and a 1-year high of $11.41.

Sagimet Biosciences (NASDAQ:SGMT - Get Free Report) last issued its quarterly earnings data on Wednesday, March 11th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.14. Research analysts expect that Sagimet Biosciences will post -1.6 EPS for the current fiscal year.

Sagimet Biosciences Company Profile

Sagimet Biosciences NASDAQ: SGMT is a clinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases. The company's lead program, CM-101, is a first-in-class fusion protein designed to neutralize the chemokine CCL24 and interrupt key drivers of tissue fibrosis. Preclinical data have demonstrated CM-101's potential to block fibrotic signaling pathways in multiple organ systems, and the company has advanced the program into early-stage clinical evaluation for indications such as nonalcoholic steatohepatitis and systemic sclerosis.

In addition to CM-101, Sagimet maintains a pipeline of preclinical candidates targeting inflammation-driven fibrotic processes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.